Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 8/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14345157 | 0.94 | KCNH2 (0.55) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14009641 | 0.94 | KCNH2 (0.55) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14009597 | 0.90 | KCNH2 (0.57) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14009603 | 0.85 | NR1I2 (0.57) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13940556 | 0.85 | NR1I2 (0.56) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL3893256 | 0.84 | NR1I2 (0.61) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL876909 | 0.84 | NR1I2 (0.63) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL3893542 | 0.84 | NR1I2 (0.61) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13965938 | 0.83 | NR1I2 (0.59) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL4554674 | 0.83 | NR1I2 (0.59) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456167-B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456167-B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| WO-2007140254-A2 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070275947-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-29 | — | — | US | disclosed |
| US-20070275947-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275947-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | NR1I2 298/4885KCNH2 2019/4885CYP3A4 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.